Identify R&D opportunities through pipeline benchmarking, clinical-stage analysis, unmet needs, collaborations, licensing, mergers and acquisitions.Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Atopic ...
For decades, the relationship between food allergies and eczema/atopic dermatitis (AD) has been one of the most contentious ...
Early-life factors, including family allergy history and moisturiser use, may help predict eczema risk in infants, according ...
The marked differences of how a JAK inhibitor and an anti-IL-4 inhibitor affect proteomics in the treatment of AD provide new ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Evommune, Inc. (NYSE:EVMN) announced on September 8 that EVO756 missed its primary endpoint in a randomized, double-blind, placebo-controlled Phase 2b trial involving 121 adults with ...
Please provide your email address to receive an email when new articles are posted on . Sanofi stated the drug’s discontinuation was based on a lack of meaningful improvement to the standard of care ...
Sanofi SAN1.53%increase; up pointing triangle said it decided against seeking regulatory approval for a new eczema drug as the French pharmaceutical company reviews its pipeline following the ...
Apogee has big plans for zumilokibart beyond eczema. (imagedepotpro/iStock/Getty Images Plus) Apogee Therapeutics has secured a promise of up to $1.3 billion in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results